GlassScriptPhysician profile
Nichole M Potts
NPI 1174957666
$1,371.40
in general payments reported to CMS, 2019-2025
26 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $61.03 · 2023: $89.78 · 2024: $419 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $188.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $111.93 | 2024-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $111.33 | 2021 | |
| Novo Nordisk INC | $91.93 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.89 | 2023-2025 | Xifaxan |
| Dexcom, INC. | $79.91 | 2024-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $76.34 | 2021-2022 | |
| Dynavax Technologies Corporation | $71.32 | 2024-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $58.27 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $54.03 | 2024-2025 | |
| Glaxosmithkline, LLC. | $52.70 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Alkermes, INC. | $49.99 | 2021 | |
| Abbott Laboratories | $38.73 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.22 | 2021 | |
| Pfizer INC. | $34.52 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.06 | 2024 | Jardiance |
| Electromed, INC. | $30.61 | 2025 | Smartvest |
| Insulet Corporation | $25.46 | 2025 | Omnipod |
| Cequr Corporation | $22.11 | 2024 | Cequr Simplicity |
| Axsome Therapeutics, INC. | $19.33 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $18.79 | 2024 | Quviviq |
| Kyowa Kirin, INC. | $16.47 | 2021 | |
| Sumitomo Pharma America, INC. | $16.21 | 2024 | Gemtesa |
| Eisai INC. | $14.22 | 2024 | |
| Exact Sciences Corporation | $13.99 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $13.45 | 2023 | Austedo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nichole Potts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.